Accessibility Menu
 
Recordati Industria Chimica E Farmaceutica S.p.A. logo

Recordati Industria Chimica E Farmaceutica S.p.A.

(OTC) RCDTF

Current Price$55.88
Market Cap$11.42B
Since IPO (2008)+617%
5 Year+19%
1 Year+2%
1 Month-2%

Recordati Industria Chimica E Farmaceutica S.p.A. Financials at a Glance

Market Cap

$11.42B

Revenue (TTM)

$2.62B

Net Income (TTM)

$443.62M

EPS (TTM)

$2.39

P/E Ratio

22.96

Dividend

$1.48

Beta (Volatility)

0.05 (Low)

Price

$55.88

Volume

431

Open

$55.88

Previous Close

$55.88

Daily Range

$55.88 - $55.88

52-Week Range

$55.88 - $65.44

RCDTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Recordati Industria Chimica E Farmaceutica S.p.A.

Industry

Pharmaceuticals

Employees

4,693

CEO

Robert Koremans, MD

Headquarters

Milan, MI 20148, IT

RCDTF Financials

Key Financial Metrics (TTM)

Gross Margin

68%

Operating Margin

27%

Net Income Margin

17%

Return on Equity

24%

Return on Capital

17%

Return on Assets

8%

Earnings Yield

4.36%

Dividend Yield

2.65%

Payout Ratio

60.31%

Stock Overview

Market Cap

$11.42B

Shares Outstanding

204.36M

Volume

431

Avg. Volume

474.889

Financials (TTM)

Gross Profit

$1.79B

Operating Income

$719.74M

EBITDA

$887.00M

Operating Cash Flow

$596.90M

Capital Expenditure

$85.12M

Free Cash Flow

$511.77M

Cash & ST Invst.

$428.82M

Total Debt

$23.85M

Recordati Industria Chimica E Farmaceutica S.p.A. Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$662.22M

+10.7%

Gross Profit

$472.65M

+14.3%

Gross Margin

71.37%

N/A

Market Cap

$11.42B

N/A

Market Cap/Employee

$2.49M

N/A

Employees

4,580

N/A

Net Income

$117.34M

+50.2%

EBITDA

$230.86M

+33.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$404.98M

+35.2%

Accounts Receivable

$590.05M

+8.6%

Inventory

$539.80M

+6.6%

Long Term Debt

$0.00

N/A

Short Term Debt

$23.85M

+4.4%

Return on Assets

8.45%

N/A

Return on Invested Capital

17.14%

N/A

Free Cash Flow

$145.23M

+120.8%

Operating Cash Flow

$172.57M

+49.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CHJTFCSPC Pharmaceutical Group Limited
$1.05+2.94%
CSPCYCSPC Pharmaceutical Group Limited
$4.30+1.11%
BDULFBangkok Dusit Medical Services Public Company Limited
$0.66+0.00%
BDUUFBangkok Dusit Medical Services Public Company Limited
$0.65+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$99.62+0.05%
NOKNokia
$13.30+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.07+0.05%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.70+0.01%

Questions About RCDTF

What is the current price of Recordati Industria Chimica E Farmaceutica S.p.A.?

Recordati Industria Chimica E Farmaceutica S.p.A. is trading at $55.88 per share.

What is the 52-week range for Recordati Industria Chimica E Farmaceutica S.p.A.?

Over the past 52 weeks, Recordati Industria Chimica E Farmaceutica S.p.A. has traded between $55.88 and $65.44.

How much debt does Recordati Industria Chimica E Farmaceutica S.p.A. have?

As of the most recent reporting period, Recordati Industria Chimica E Farmaceutica S.p.A. reported total debt of $2.90B.

How much cash does Recordati Industria Chimica E Farmaceutica S.p.A. have on hand?

Recordati Industria Chimica E Farmaceutica S.p.A. reported $503.63M in cash and cash equivalents in its most recent financial results.

What is Recordati Industria Chimica E Farmaceutica S.p.A.’s dividend yield?

Recordati Industria Chimica E Farmaceutica S.p.A. currently has a dividend yield of 2.65%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.